scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of scPharmaceuticals in a research report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of $0.70 per share for the year. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for scPharmaceuticals' current full-year earnings is ($1.53) per share.
Separately, Craig Hallum reduced their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, November 14th.
Read Our Latest Analysis on SCPH
scPharmaceuticals Price Performance
NASDAQ SCPH traded down $0.19 on Wednesday, reaching $2.93. The company had a trading volume of 1,962,538 shares, compared to its average volume of 316,087. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $146.62 million, a PE ratio of -1.54 and a beta of 0.40. The firm's 50 day moving average price is $3.37 and its 200 day moving average price is $3.93. scPharmaceuticals has a 12 month low of $2.91 and a 12 month high of $6.20.
Institutional Trading of scPharmaceuticals
A number of large investors have recently made changes to their positions in SCPH. BNP Paribas Financial Markets increased its holdings in shares of scPharmaceuticals by 116.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company's stock worth $26,000 after buying an additional 3,101 shares during the last quarter. Legato Capital Management LLC purchased a new position in shares of scPharmaceuticals during the 4th quarter worth about $37,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of scPharmaceuticals during the 4th quarter worth about $38,000. Virtu Financial LLC purchased a new position in shares of scPharmaceuticals during the 3rd quarter worth about $46,000. Finally, ProShare Advisors LLC purchased a new position in shares of scPharmaceuticals during the 4th quarter worth about $48,000. 89.52% of the stock is currently owned by institutional investors.
About scPharmaceuticals
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
See Also
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
